Physician profile
Laura Harbin
NPI 1093235715
$2,102.30
in general payments reported to CMS, 2019-2025
17 companies · $611 in 2025
The $611 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $1,029 · 2024: $263 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,000 · Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,000.00 |
| Food and Beverage | $902.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,028.98 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $280.70 | 2024-2025 | Jemperli, Zejula |
| Eisai INC. | $206.83 | 2024-2025 | |
| Stryker Corporation | $156.28 | 2022 | |
| Merck Sharp & Dohme LLC | $96.32 | 2024-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $53.09 | 2025 | Imfinzi |
| Integra Lifesciences Corporation | $52.32 | 2024-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Seagen INC. | $43.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.38 | 2025 | |
| Genmab U.S., INC. | $23.15 | 2025 | Epkinly |
| Daiichi Sankyo INC. | $22.65 | 2025 | Injectafer |
| Kyowa Kirin, INC. | $21.19 | 2025 | |
| Myriad Genetic Laboratories, INC. | $20.56 | 2024 | Mychoice Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $20.03 | 2025 | Ninlaro |
| Ethicon US, LLC | $19.02 | 2025 | Enseal |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $18.42 | 2025 | Clonoseq |
| Geron Corporation | $15.01 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Harbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.